EFESO: Juvenile-onset eosinophilic fasciitis characterization
International Multicentre Cohort Study on Clinical Manifestations and Response to Therapy in Juvenile Onset Eosinophilic Fasciitis
This project will collect information from children diagnosed with eosinophilic fasciitis to see if adult diagnostic rules and common treatments fit pediatric patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | N/A to 18 Years |
| Sex | All |
| Sponsor | Meyer Children's Hospital IRCCS Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 15 sites (Birmingham, Alabama and 14 other locations) |
| Trial ID | NCT07348263 on ClinicalTrials.gov |
What this trial studies
This is an observational, multicenter effort to gather clinical, diagnostic, and treatment data on patients diagnosed with juvenile-onset eosinophilic fasciitis from 2000 through 2026. Participants must have been diagnosed before age 18 and have at least six months of follow-up, with data contributed under local informed consent rules. The registry will compare pediatric presentations to adult diagnostic criteria, document the role of skin biopsy in children, and record outcomes with common therapies such as glucocorticoids and methotrexate. Data will come from participating centers in Europe and the United States to better define pediatric diagnostic and therapeutic pathways.
Who should consider this trial
Good fit: Children diagnosed with eosinophilic fasciitis before age 18 between 2000 and 31 December 2026 who have at least six months of follow-up and provide informed consent are ideal candidates.
Not a fit: Patients diagnosed at age 18 or older, those with less than six months of follow-up, or those unwilling to provide consent are not likely to benefit from participation.
Why it matters
Potential benefit: If successful, the project could improve how clinicians classify and treat children with eosinophilic fasciitis, potentially reducing invasive testing and optimizing therapy choices.
How similar studies have performed: Adult studies report benefit from combinations like glucocorticoids and methotrexate, but pediatric-specific data are limited and the adult diagnostic rules have not been validated in children.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criterai: All patients diagnosed from 2000 to 31/12/2026 * minimum follow-up 6 months * Age \<18 years at diagnosis; * All patients whose informed consent is collected in accordance with current local legislation will also be considered enrollable. Exclusion Criteria: * Age ≥18 years at diagnosis; * Unwilling to participate into the study; * A follow-up period \< 6 months.
Where this trial is running
Birmingham, Alabama and 14 other locations
- University of Alabama at Birmingham — Birmingham, Alabama, United States (Recruiting)
- SUNY Upstate Pediatric Rheumatology — Syracuse, New York, United States (Recruiting)
- Children's Hospital Zagreb — Zagreb, Croatia (Recruiting)
- Hamburger Zentrum für Kinder- und Jugendrheumatologie - — Hamburg, Germany (Not_yet_recruiting)
- Ruth Rappaport Children's Hospital of Haifa — Haifa, Israel (Not_yet_recruiting)
- Meyer Children's Hospital IRCCS — Florence, Fi, Italy (Recruiting)
- IRCCS Giannina Gaslini, — Genova, Italy (Recruiting)
- Università di Udine — Udine, Italy (Not_yet_recruiting)
- Iuliu Hatieganu University of Medicine and Pharmacy — Cluj-Napoca, Romania (Recruiting)
- University Children's Hospital — Ljubljana, Slovenia (Not_yet_recruiting)
- Hospital Sant Joan de Déu, — Barcelona, Spain (Not_yet_recruiting)
- Astrid Lindgren Children's Hospital — Solna, Stockholm County, Sweden (Recruiting)
- Cerrahpasa Medical School, Istanbul University — Istanbul, Turkey (Türkiye) (Not_yet_recruiting)
- Alder Hey Children's Hospital — Liverpool, United Kingdom (Recruiting)
- Great North Children's Hospital, Newcastle Upon Tyne — Newcastle upon Tyne, United Kingdom (Not_yet_recruiting)
Study contacts
- Study coordinator: Edoardo Marrani
- Email: edoardo.marrani@meyer.it
- Phone: +390555662913
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.